

An Adjudication Protocol for Severe Bacterial and Viral Pneumonia

Chiagozie I. Pickens,¹ Catherine A. Gao,¹ James M. Walter,¹ Jacqueline M. Kruser,^{1,2} Helen K. Donnelly,¹ Alvaro Donayre,¹ Katie Clepp,¹ Nicole Borkowski,¹ Richard G. Wunderink,¹ Benjamin D. Singer,¹ The NU SCRIPT Study Investigators

¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

²Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin, Madison, WI, USA

*Address Correspondence to:

Chiagozie Pickens MD
Division of Pulmonary and Critical Care
Northwestern University Feinberg School of Medicine
303 E. Superior Street
Simpson Querrey 5th Floor, Suite 5-406
Chicago, IL 60611
Phone: 312-695-3562 (office)
Email: chiagozie-ononye@northwestern.edu

Author Contributions

CIP, CAG, JMW, RGW, JMK and BDS wrote and edited the manuscript and performed data analysis.

CIP, CAG, JMW, JMK, RGW and BDS adjudicated the episodes of pneumonia.

RGW led the conceptualization and methodology of the adjudication process.

HKD, AD, KC and NB prepared the forms for adjudication, performed data entry and organized the committee reviews.

All authors confirm that they had full access to all the data in the study and accept responsibility to submit for publication. All authors read and approved the final draft of the manuscript.

Acknowledgements: The authors would like to acknowledge Nikolay Markov for programming assistance.

Funding: National Institutes of Health, National Institute of Allergy and Infectious Diseases (AI135964), Northwestern Memorial Hospital Masters in Medicine Institutional Grant. CAG is supported by NIH awards T32HL076139 and F32HL162377. JMK is supported by NIH/NHLBI K23HL146890. RGW is supported by NIH grants U19AI135964, U01TR003528, P01HL154998, R01HL14988, R01LM013337. BDS is supported by NIH awards R01HL149883, R01HL153122, P01HL154998, P01AG049665, and U19AI135964.

Declaration of interests: BDS holds US patent 10,905,706, "Compositions and methods to accelerate resolution of acute lung inflammation," and serves on the Scientific Advisory Board of Zoe Biosciences, for which he holds stock options. Other authors declare no conflicting interests.

Running Head: Adjudication of Severe Pneumonia

Word counts: Abstract 325 Manuscript 3252

Abstract

Rationale: Clinical endpoints that constitute successful treatment in severe pneumonia are difficult to ascertain and vulnerable to bias. Utility of a protocolized adjudication procedure to determine meaningful endpoints in severe pneumonia is not well described.

Objectives: To develop and validate a protocol for classification and adjudication of clinical endpoints in severe bacterial and viral pneumonia in a prospective cohort of critically ill, mechanically ventilated patients.

Methods: Each episode of pneumonia was independently reviewed by two of six pulmonary and critical care physician adjudicators. If a discrepancy in at least one critical answer occurred between the two adjudicators, a third adjudicator reviewed the case and answered the specific question(s) for which there was a lack of agreement. If discrepancy remained after all three adjudications, consensus was achieved through committee review.

Results: Evaluation of 784 pneumonia episodes during 593 hospitalizations achieved a 79% crude rate of interobserver agreement defined as agreement between 2 of 3 reviewers. Culture-negative pneumonia was associated with increased interobserver agreement. Multiple episodes of pneumonia and bacterial and viral co-infection in the initial episode of pneumonia were associated with decreased interobserver agreement. For bacterial pneumonia, patients with an adjudicated day 7-8 clinical impression of cure for the initial episode of pneumonia were more likely to be discharged alive compared to patients with a day 7-8 clinical impression of indeterminate ($p < 0.01$), superinfection ($p = 0.03$), or a combined impression of persistence and superinfection ($p = 0.04$). In viral pneumonia, patients with an adjudicated clinical impression of cure for an initial episode of viral pneumonia were more likely to be discharged alive compared to patients with an adjudicated clinical impression of persistence ($p < 0.01$), indeterminate ($p < 0.01$), or bacterial superinfection ($p < 0.01$).

Conclusions: We developed and validated a protocol for classification and adjudication of clinical endpoints in severe pneumonia. This protocol can be applied to cohorts of patients with severe pneumonia to provide uniform assessment of patient-centered endpoints.

Introduction

In severe pneumonia, endpoints such as death or extubation failure are easily ascertained, while other endpoints like clinical cure, microbiologic resolution, improvement in oxygenation and safety are not standardized and subject to bias in interpretation.¹ In studies with complex endpoints of interest, particularly events that require some analysis of clinical information, study protocols use adjudication committees to provide consistent, unbiased determination of the presence or absence of a diagnosis or an event.²⁻⁴ Adjudication committees are established components of large cohort studies and randomized clinical trials in cardiovascular disease, oncology, interstitial lung disease and sepsis.^{2,5-9}

The process of adjudicating clinical endpoints in a large cohort of patients with severe pneumonia is not well described, although it is frequently incorporated into critical care trials.¹⁰ Existing studies that leverage an adjudication committee for pneumonia do not describe the process or the reliability of the method in detail.¹¹⁻¹³ For example, recurrent pneumonia was utilized as an endpoint in a study of microbiological treatment failure in bacterial pneumonia, but the adjudication process used to ascertain the endpoint was not outlined.¹⁴ A large randomized controlled trial (RCT) of community-acquired pneumonia (CAP) employed an endpoint adjudication committee to determine the primary outcome, clinically indicated treatment with antibiotics, but did not detail the validity of the adjudication process.¹⁵ Other literature focuses on diagnostic adjudication in pneumonia and does not address endpoint adjudication. For example, a study by Cook et al reported a crude agreement rate ranging from 50% to 82% when two adjudicators evaluated ventilator-associated pneumonia (VAP) in patients enrolled in a randomized controlled trial; however, this study was performed almost 25 years ago and focused on VAP, limiting the generalizability of these findings to a broader patient population with severe pneumonia.¹⁶ A 2013 study by Klouwenberg et al described interobserver agreement between clinicians identifying the source of infection and the plausibility of infection in critically ill patients with sepsis using the Centers for Disease Control and Prevention criteria, finding the lowest rate of interobserver agreement in VAP with only 35% full diagnostic agreement between two observers.¹⁷ The authors concluded the CDC criteria are insufficient to assess complex infections like pneumonia. Additionally, a prospective study on infection in patients with the systemic inflammatory response syndrome reported that the lowest rate of physician agreement occurred when identifying the presence of pneumonia.¹⁸ These studies describe the complexity of diagnosing pneumonia but do not address methods for standard identification of clinical endpoints in pneumonia.

We developed a protocol for adjudication of clinical endpoints for a prospective cohort of critically ill, mechanically ventilated patients with suspected pneumonia. We hypothesized that our procedures reliably assess endpoints and exhibit construct validity in patients with severe pneumonia. Our results suggest that our protocol is a useful and valid tool to provide uniform and consistent identification of endpoints in bacterial and viral pneumonia.

Methods

This adjudication protocol was developed to assess episodes of pneumonia for patients enrolled in the single-center **S**uccessful **C**linical **R**esponse **I**n **P**neumonia **T**herapy (SCRIPT) study (Northwestern University IRB #STU00204868). SCRIPT is an NIH/NIAID-sponsored U19 Systems Biology Center that uses a multi-omics approach to analyzing pathogen, host defense and microbiome factors in order to understand the response to severe pneumonia at the alveolar level. SCRIPT is a prospective, observational cohort study of mechanically ventilated patients with suspected pneumonia. In the medical intensive care unit (ICU) at Northwestern Memorial Hospital (NMH), bronchoalveolar lavage (BAL) or non-bronchoscopic BAL (NBBAL) is routinely performed to confirm presence and identify etiology of pneumonia in intubated patients.^{19–22} In this manuscript, the term BAL will encompass both bronchoscopic and non-bronchoscopic BAL procedures. Our adjudication protocol was developed prior to the start of patient enrollment in the SCRIPT study in 2018 and subsequently modified during the COVID-19 pandemic in 2020 to include adjudication of primary viral pneumonia and viral pneumonia complicated by bacterial superinfection.

Clinical Endpoints

Our protocol was designed to ascertain a final clinical endpoint at the time of death or hospital discharge as well as interim clinical endpoints. The interim clinical endpoints were defined as Cure, Indeterminate, Persistence or Superinfection. See the Supplement for detailed definitions of each term. For bacterial pneumonia or bacterial and viral co-infection pneumonia interim clinical endpoints were assessed at day 7-8, day 10 and day 14, corresponding to common antibiotic discontinuation time points in clinical trials and clinical practice. Endpoints were defined based on literature review and expert consensus.^{23–25} Because part of our objective was to evaluate patients at various time points during an episode of pneumonia, we did not use traditional measures like mortality, ventilator-free days or microbiological cure as stand-alone endpoints.

Pneumonia Episode Definition

We defined the initial episode of pneumonia by the date of the clinical BAL procedure that prompted enrollment into SCRIPT. An episode of pneumonia ended when systemic antibiotics for pneumonia were discontinued without recurrent signs of pneumonia for at least 48 hours (defined in detail in the Supplement). Onset of subsequent episodes within the same hospitalization were likewise defined by the timing of a diagnostic BAL procedure occurring after at least 48 hours off antibiotics directed at pneumonia and without recurrent or worsening signs of pneumonia during the interval. We applied standard definitions for pneumonia^{26,27} at the time of each BAL procedure. See the Supplement for descriptions of clinical community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) and additional definitions used to standardize the adjudication process. Importantly, the definitions of CAP, HAP and VAP were applied based on the duration of admission or ventilation preceding the time of BAL sampling irrespective of the timing or locale of symptom onset. We defined episodes on and subsequent to the date of the SCRIPT study enrollment BAL procedure up to day 99, censoring any episodes preceding SCRIPT enrollment or beginning after day 99.

Adjudication Committee

The adjudication committee was composed of six pulmonary and critical care physicians at Northwestern Medicine. Two adjudicators independently and retrospectively reviewed each patient's complete electronic health record (EHR) and entered written responses to each question on the evaluation form (included in the Supplement). Review was conducted after the patient's hospital discharge. If both adjudicators provided the same responses to all questions on the evaluation form, consensus was achieved. If discrepancy in at least one response occurred, the discrepant question was highlighted on a new, blank evaluation form and given to a third adjudicator who answered the specific question based on chart review, blinded to the previous reviewers' responses. Agreement between the third reviewer and one of the original reviewers was considered the final response. If a discrepancy remained between all three reviewers, a committee review was performed with a minimum of three adjudicators present, and a consensus answer was provided by the committee. If a case was identified by the first reviewer as a non-pneumonia episode, this classification was confirmed by a second reviewer if requested by the first reviewer. The first reviewer could request committee review for unusual, complex cases.

Committee adjudication took place in person or by video conference on a weekly basis. The total committee group membership at any time point was five physicians. The committee held several meetings for quality control to ensure the manual data entered into the adjudication worksheet aligned with the data entered into the electronic database and the designated etiologies for pneumonia (i.e., viral, bacterial, co-infection, culture-negative, non-pneumonia and indeterminate) were accurate per written guidelines available to all committee members (included in the Supplement).

Adjudication Worksheet

The full adjudication worksheet consisted of 20 questions and is included in the Supplement. Depending on the complexity of the case and the branching logic of the form, not all questions required a response. Additionally, some questions had objective, numerical answers that did not require multi-reviewer concordance to resolve discrepancies. Because the answers to these questions could be identified by chart review, a research coordinator reviewed the case to resolve discrepant responses to these questions rather than involving a third reviewer: (1) Number of days antibiotics were given for viral-only pneumonia, (2) If initial sample, has the patient been actively treated for pneumonia for more than 24 hours prior to sample collection, (3) Are serial procalcitonin values available, and (4) Level of evidence for extrapulmonary infection.

Statistical Analysis

Statistical analysis was performed using R Studio (RStudio 2022.07.0: Integrated Development for R. RStudio, PBC, Boston, MA). The Sankey diagram in Figure 1 was created using Python 3.9. Comorbidities were mapped using ICD codes with Charlson Comorbidity Index definitions, with only comorbidities present before admission contributing to totals. Pearson's Chi-squared or Fisher's exact test with Bonferroni correction for multiple comparisons was performed for outcomes with categorical variables. The conditional maximum likelihood estimator was used to

report odds ratios. Crude rates of interobserver agreement were calculated. To estimate a probability of chance agreement for the Cohen's Kappa Statistic (observed agreement - chance agreement/1-chance agreement) we calculated the probability of chance agreement on three mandatory questions: Appropriate antibiotics (3 response options), Clinical Impression (5 response options) and the Overall Global Clinical Cure (2 response options). This resulted in a 0.04 probability of chance agreement.

Results

From June 2018 to June 2022, 784 pneumonia episodes from 593 hospitalizations were adjudicated. Patient demographics and clinical characteristics are listed in Table 1.

Variables	N (%)
Age (Median [IQR])	62 [51,72]
Gender	
Male	298 (59.1%)
Female	206 (40.9%)
Ethnicity	
Hispanic	104 (20.6%)
Not Hispanic or Latino	377 (74.8%)
Not answered	23 (4.6%)
Race (Self-Identified)	
African-American or Black	100 (19.8%)
American Indian or Alaska Native	4 (0.8%)
Asian	17 (3.4%)
Native Hawaiian or Other Pacific Islander	1 (0.2%)
White	297 (58.9%)
Not answered	85 (16.8%)
Pneumonia Category for Initial Episode (n = 593)	
Clinical CAP	137 (23.1%)
Clinical HAP	202 (34.1%)
Clinical VAP	160 (27.0%)
Non-pneumonia episode (37 single reviewer, 57 adjudicated)	94 (15.9%)
Pneumonia Etiology (n = 519)	
Viral only	153 (25.8%)
Bacterial only	150 (25.3%)
Viral/bacterial co-infection	87 (14.7%)
Indeterminate	3 (0.1%)
Culture-negative	106 (17.9%)
Number of Episodes (n = 593)	
Multiple episodes	122 (20.6%)
Single episode	471 (79.4%)
Comorbid Conditions	
Cerebrovascular disease	124 (20.9%)
Congestive heart failure	173 (29.2%)
Malignancy	200 (33.7%)
Diabetes	213 (35.9%)
Chronic pulmonary disease	212 (35.7%)
Liver disease	155 (25.2%)
Renal disease	159 (26.8%)
Hospitalization	
Hospital length of stay (median, interquartile range [IQR])	23 [13,37]
ICU length of stay (median, [IQR])	14 [6,25]
Patients with day 7-8 adjudication*	257 (60.0%)
Hospital mortality	189 (37.5%)

Table 1. Demographics of participants with adjudicated episodes of pneumonia.

*Patients with viral only pneumonia, non-pneumonia and those who were deceased, discharged or transferred to another facility prior to day 7-8 did not have a day 7-8 adjudication.

37/593 (6.2%) hospitalizations were not reviewed by multiple adjudicators because the first reviewer identified the episode(s) as non-pneumonia or requested an expedited committee review for unusual or previously undefined conditions; thus the total number of hospitalizations reviewed by multiple adjudicators was 556 (Figure 1). 262/556 (47.1%) hospitalization-level examinations had an interobserver concordance between two adjudicators and did not require a third adjudicator; hence, 294/556 (52.9%) patient cases went to a third reviewer to evaluate at least one point of disagreement. 117 of the 239 cases that required a third reviewer had a discrepancy between all three adjudicators and required a committee review to arrive at a final agreement on the appropriate endpoint(s) for the patient. Thus, overall consensus (either agreement of 2/2 or 2/3 reviewers) without the need for committee review was achieved in 439/556 (78.9%) cases.




Figure 1. Sankey diagram illustrating the adjudication process. Out of 593 hospitalizations, 37 had only one reviewer (R1), 262 cases had two reviewers (R2), 294 cases required a third reviewer (R3). A small subset went directly to committee review after R1 and R2.

To identify differences in the rates of consensus agreement over time, we calculated crude rates of interobserver agreement by year (Figure 2). At least two reviewers adjudicated 41 cases from 2018, 110 cases from 2019, 258 cases from 2020, 124 cases from 2021 and 23 cases from 2022. In the years spanning 2018 to 2022, interobserver agreement defined as agreement between two of two adjudicators was 54%, 51%, 41%, 52% and 57% respectively. The Cohen's Kappa coefficient per year for interobserver agreement based on agreement between two of two adjudicators was 0.52, 0.49, 0.39, 0.50 and 0.55, respectively. When interobserver agreement was defined as agreement between 2 of 3 adjudicators, the crude rate of agreement increased to 85.4%, 85.5%, 69.8%, 86.3% and 100% agreement. A test for proportions demonstrated a significant difference in interobserver agreement by year ($X^2 = 27.1$, $df = 4$, $p = < 0.001$). A test for proportions excluding 2020 demonstrated no significant difference in interobserver agreement between 2018, 2019, 2021 and 2022 ($X^2 = 3.8$, $df = 3$, $p = 0.28$), reflecting the temporal reliability of the adjudication protocol outside of the early pandemic year 2020.




Figure 2. Crude rates of interobserver agreement by year. When interobserver agreement was defined as consensus between 2 of 2 reviewers, the crude rates of interobserver agreement did not exceed 0.6. Interobserver agreement defined as agreement between 2 of 3 reviewers increased the rate of agreement.

We sought to determine whether the etiology of the initial pneumonia episode and the number of pneumonia episodes in a given hospitalization were associated with interobserver agreement, defined as consensus between 2 of 3 reviewers without the need for committee review. The proportion of initial pneumonia episodes that were CAP, HAP or VAP did not differ between cases that had consensus without committee review and cases that required committee review for consensus. The odds ratio for consensus from 2 of 3 reviewers for CAP was 0.78 (95% CI [0.49, 1.24]), for HAP was 1.17 (95% CI [0.75, 1.85]) and for VAP was 0.76 (95% CI [0.48 to 1.21]).

We calculated the odds of interobserver agreement based on the microbiologic etiology of pneumonia. For example, for pneumonia with a defined bacterial etiology, we divided the odds of interobserver agreement among the cases with an initial episode of pneumonia with a defined bacterial etiology by the odds of interobserver agreement among the cases where the initial episode was not bacterial pneumonia. An odds ratio > 1 suggests a higher proportion of interobserver agreement in the adjudication worksheet and less need for committee review of at least one of the critical elements of the adjudication worksheet. Initial episodes of pneumonia that were bacterial and viral co-infection were associated with lower interobserver agreement (OR =

0.57, 95% CI [0.33, 0.98]) (Figure 3). Initial episodes of pneumonia that were culture-negative were significantly associated with higher interobserver agreement (OR = 2.15, 95% CI [1.13, 4.36]). The presence of multiple episodes was strongly associated with a committee review required to achieve consensus (OR = 0.13, 95% CI [0.08, 0.20]). Initial episodes of pneumonia that were viral only did not have a significant difference in the odds of interobserver agreement versus committee review to achieve consensus (OR = 0.64, 95% CI [0.40, 1.01]).




Figure 3. The odds of interobserver agreement based on characteristics of the initial episode of pneumonia.

To determine the construct validity of our clinical endpoints, we assessed the discharge disposition based on the day 7-8 adjudicated clinical endpoint of the initial pneumonia episode. A day 7-8 adjudicated clinical endpoint was available for 311 hospitalizations; 282 did not have a day 7-8 clinical endpoint for the initial episode because 94 were non-pneumonia episodes, 153 had viral infection only and 35 were discharged, transferred to another hospital or died prior to a day 7-8 assessment. Discharge dispositions were grouped into favorable outcomes (home, acute inpatient rehabilitation, skilled nursing facility, long term acute care facility) versus unfavorable outcomes (death or hospice). As demonstrated in Figure 4, the proportion of patients discharged to favorable versus unfavorable dispositions differed by the day 7-8 clinical endpoint of the initial episode of pneumonia.




Figure 4. The association between day 7-8 clinical endpoints (cure, indeterminate, persistent or superinfection) for the initial episode of bacterial or bacterial-viral co-infection pneumonia and discharge disposition at the end of the hospitalization. Day 7 P and S is an abbreviation for Persistence and Superinfection. *Deceased includes patients who underwent lung transplantation for refractory respiratory failure during their hospitalization. Lines with p values compare mortality rates between groups.

A higher proportion of patients with a day 7-8 clinical endpoint of cure had a favorable discharge disposition compared to patients with a day 7-8 clinical endpoint of indeterminate, superinfection or persistence with superinfection. No significant difference in discharge disposition was found when cure was compared to persistence alone. As demonstrated in Table 2, in patients with viral only pneumonia a higher proportion of patients with a clinical impression of cure were discharged to favorable dispositions compared to patients with an adjudicated clinical endpoint of indeterminate, superinfection or persistence.

Clinical Endpoints for Initial Episode of Viral Pneumonia	Control Group (Cure) Discharge Disposition		Comparison Group Discharge Disposition		p Value
	Home, AIR, SNF, LTACH	Deceased or Hospice	Home, AIR, SNF, LTACH	Deceased or Hospice	
Cure	47	3	--	--	NA
Persistence	--	--	0	19	<0.01
Indeterminate	--	--	0	15	<0.01
Superinfection	--	--	37	30	<0.01

Table 2. Differences in hospital discharge disposition based on the adjudicated clinical endpoints of patients with severe viral pneumonia.

Discussion

We developed and validated an adjudication protocol for severe bacterial and viral pneumonia in intubated patients. Pneumonia is a complex clinical syndrome with poorly defined endpoints for treatment success or failure. Because of this, the FDA suggests all-cause mortality at 14 to 28 days as a primary endpoint for noninferiority registration clinical trials of new therapy for bacterial HAP and VAP.²⁸ However, mortality fails to capture important patient-centered outcomes.²⁹ Using the Delphi method, a panel of international experts attempted to establish a consensus composite endpoint for clinical trials related to HAP and VAP.²⁰ The panel discussed a range of possible endpoints, including clinical cure, ventilator-free days, decrease in clinical pulmonary infection score (CPIS), microbiological cure, safety, change in procalcitonin and acquisition of antimicrobial resistance. The range of proposed endpoints highlight the complexity that clinicians and researchers face when evaluating whether a patient with pneumonia had a favorable or unfavorable outcome. In the aforementioned study by Weiss et al, clinical cure was ranked as the most important primary outcome, yet a universally accepted definition for clinical cure in pneumonia does not exist. Weiss and colleagues used an iterative process to ultimately define clinical cure as resolution of signs and symptoms of infection, improvement in oxygenation and no appearance of new signs of sepsis. In this study, we incorporate these clinical characteristics into our definition of cure at day 7-8, day 10 and day 14.

Our protocol for clinical classification and adjudication of episodes of pneumonia resulted in a 79% overall crude rate of consensus agreement on clinical endpoints when two adjudicators independently reviewed episodes of pneumonia and a third adjudication was available to resolve discrepancies. Based on literature review, our consensus agreement rate falls within the realm of “strong” or “substantial” agreement.³⁰ Sjoding et al reported a similar finding in which the addition of a third reviewer improved interobserver reliability for adjudication of complex clinical cases of ARDS.³¹ The extent of our adjudication worksheet minimizes the probability that two observers could provide the same responses to all of the questions by chance. In a highly cited review, McHugh et al advise researchers to rely on the kappa statistic if there is likely to be much guessing between observers, but if raters are well trained and there is low likelihood of guessing, it is safe to rely on percent agreement as a reflection of interrater reliability.³²

In our study, the presence of multiple episodes of pneumonia during a hospitalization was associated with lower odds of consensus by interobserver agreement. An initial episode of bacterial/viral co-infection pneumonia also decreased the odds of consensus by interobserver agreement. This finding likely reflects the increased complexity of assessing co-infection, particularly when microbiologic resolution for one pathogen and persistence of the other exists. Conversely, interobserver agreement was significantly higher for culture-negative cases. The reason for this is unclear but may be related to the fact that there are few variables to consider when determining whether or not the infection has resolved in culture negative cases. For example, decrease in colony forming units of an organism does not apply to culture-negative cases.

We observed a statistical decrease in agreement for episodes occurring in 2020 during the early portion COVID-19 pandemic, in which our adjudication methods for viral pneumonia were

changed to accommodate the high numbers of SARS-CoV-2 pneumonia cases in our cohort. Use of a new instrument that required iterative clarification of definitions in the midst of a large increase in cases enrolled contributed to the higher rates of discrepancies. In addition, patients with SARS-CoV-2 pneumonia had complex clinical courses, which may have challenged objective identification of disease resolution.

For patients with bacterial pneumonia, we identified an association between day 7-8 adjudicated clinical endpoint of cure and discharge from the hospital alive compared to a day 7-8 adjudicated clinical endpoint of indeterminate, superinfection or combined persistence and superinfection. For patients with viral pneumonia, we identified an association between a clinical endpoint of cure and discharge from the hospital alive compared with an adjudicated clinical endpoint of indeterminate, superinfection or persistence. This important association between adjudicated endpoints and objective outcomes supports the construct validity of our procedures and suggests that hospital mortality is linked with the clinical course of severe pneumonia at day 7-8 of the pneumonia episode.

Our study has limitations. We did not obtain input from independent observers, such as the physicians treating the patient, to benchmark the results from the adjudication committee, although we did review all clinical documentation from the bedside teams during our case reviews. Clinical adjudication committees are controversial and some studies report no difference in the rate of events reported by individual observers compared with the committee. Another limitation is the external validity of our findings, which may depend on the experience of the adjudicators comprising the panel. A lower agreement rate may result from clinicians less familiar with the diagnosis and management of severe pneumonia. In our study, key data incorporated into adjudications came from BAL fluid results, which may limit the generalizability of our protocol in centers where BAL sampling is used less often in pneumonia diagnosis. Nevertheless, our classification and adjudication protocol serve as a useful starting point for investigators to define clinical endpoints in severe bacterial and viral pneumonia.

References

1. Dela Cruz CS, Evans SE, Restrepo MI, et al. Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. *Ann Am Thorac Soc*. 2021;18(7):1087-1097.
2. Held C. When do we need clinical endpoint adjudication in clinical trials? *Ups J Med Sci*. 2019;124(1):42-45.
3. Kahan BC, Feagan B, Jairath V. A comparison of approaches for adjudicating outcomes in clinical trials. *Trials*. 2017;18(1):266.
4. Meah MN, Denvir MA, Mills NL, Norrie J, Newby DE. Clinical endpoint adjudication. *Lancet*. 2020;395(10240):1878-1882.
5. Seltzer JH, Turner JR, Geiger MJ, et al. Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. *Am Heart J*. 2015;169(2):197-204.
6. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. *N Engl J Med*. 2020;382(17):1599-1607.
7. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2018;198(5):e44-e68.
8. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol*. 2021;22(7):959-969.
9. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet*. 2021;398(10313):1811-1824.
10. Singh JM, Ferguson ND. Better infrastructure for critical care trials: nomenclature, etymology, and informatics. *Crit Care Med*. 2009;37(1 Suppl):S173-S177.
11. Wussler D, Kozuharov N, Tavares Oliveira M, et al. Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. *Clin Chem*. 2019;65(12):1532-1542.
12. François B, Jafri HS, Chastre J, et al. Efficacy and safety of suvatroxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. *Lancet Infect Dis*. 2021;21(9):1313-1323.
13. Johnstone J, Meade M, Lauzier F, et al. Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial. *JAMA*. 2021;326(11):1024-1033.
14. Albin OR, Henig O, Patel TS, et al. Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia. *Clin Infect Dis*. 2020;71(12):3033-3041.

15. Bielicki JA, Stöhr W, Barratt S, et al. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. *JAMA*. 2021;326(17):1713-1724.
16. Cook D, Walter S, Freitag A, et al. Adjudicating ventilator-associated pneumonia in a randomized trial of critically ill patients. *J Crit Care*. 1998;13(4):159-163.
17. Klein Klouwenberg PMC, Ong DSY, Bos LDJ, et al. Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. *Crit Care Med*. 2013;41(10):2373-2378.
18. Walker M, Hamer D, Musso M, O'Neal C, Thomas C, O'Neal H. 2151. Accuracy of Physician Adjudication of Infection in Patients with Systemic Inflammatory Response Syndrome (SIRS). *Open Forum Infectious Diseases*. 2018;5(suppl_1):S633-S634. doi:10.1093/ofid/ofy210.1807
19. Walter JM, Helmin KA, Abdala-Valencia H, Wunderink RG, Singer BD. Multidimensional assessment of alveolar T cells in critically ill patients. *JCI Insight*. 2018;3(17). doi:10.1172/jci.insight.123287
20. Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. *Nature*. 2021;590(7847):635-641.
21. Pickens CO, Gao CA, Cuttica MJ, et al. Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia. *Am J Respir Crit Care Med*. 2021;204(8):921-932.
22. Gao CA, Bailey JI, Walter JM, et al. Bronchoscopy on Intubated Patients with COVID-19 Is Associated with Low Infectious Risk to Operators. *Ann Am Thorac Soc*. 2021;18(7):1243-1246.
23. Weiss E, Zahar JR, Alder J, et al. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. *Clin Infect Dis*. 2019;69(11):1912-1918.
24. Weiss E, Essaied W, Adrie C, Zahar JR, Timsit JF. Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials. *Crit Care*. 2017;21(1):162.
25. Timsit JF, de Kraker MEA, Sommer H, et al. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net. *Intensive Care Med*. 2017;43(7):1002-1012.
26. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200(7):e45-e67.
27. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63(5):e61-e111.

28. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment Guidance for Industry. Published online June 2020. <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>
29. Veldhoen RA, Howes D, Maslove DM. Is Mortality a Useful Primary End Point for Critical Care Trials? *Chest*. 2020;158(1):206-211.
30. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. *Fam Med*. 2005;37(5):360-363.
31. Sjoding MW, Hofer TP, Co I, Courey A, Cooke CR, Iwashyna TJ. Interobserver Reliability of the Berlin ARDS Definition and Strategies to Improve the Reliability of ARDS Diagnosis. *Chest*. 2018;153(2):361-367.
32. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med* . 2012;22(3):276-282.